Female TP53 carriers have a significant risk of developing breast cancer, which can be as high as 85% by the age of 60 years [10,11], with the majority of breast cancer diagnoses being human epidermal growth factor receptor-2 (HER2) positive [12,13,14]. Here, ERBB2 is linked to breast cancer.